ИЗУЧЕНИЕ ЭФФЕКТИВНОСТИ И ПЕРЕНОСИМОСТИ ОТЕЧЕСТВЕННОГО ГИПОЛИПИДЕМИЧЕСКОГО ПРЕПАРАТА «ФЛАТЕРОН» У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА

The aim was to study the effectiveness and tolerability of the domestic bioflavonoid drug «Flateron», as a second-line lipid-lowering agent in the treatment of patients with coronary artery disease who did not reach the target level of LDL cholesterol. Material and methods. 70 patients with a diagnosis of coronary artery disease, stable angina pectoris II–III FC, randomized to groups were examined: Group 1 – the main one: patients with coronary artery disease taking Flateron capsules 100 mg (2 times a day) (n = 20). 2 – group – the main one: patients with coronary heart disease taking atorvastatin + «Flateron» capsules 100 mg (2 times a day). 3-group – comparison group: patients with coronary heart disease (n = 30), taking only atorvastatin 20 mg with titration up to 40 mg (average daily dose was 32.0 ± 8.7 mg). Basic therapy included antianginal, if necessary, antihypertensive drugs. Initially and after a month, the clinical condition of the patients was studied: heart rate, systolic blood pressure (SBP) and diastolic (DBP) in the supine position, NNA, NNT. Patients underwent such studies as ECG, echocardiography (EchoCG), veloergometry. Biochemical parameters were studied – lipid spectrum, fasting glucose, ALT, AST, bilirubin, total CPK using a Daytona biochemical analyzer (RANDOX, UK). Results. The action of the domestic herbal preparation «Flateron» produced by LLC «NIKA PHARM», was developed by the Institute of Chemistry and Plant Substances of the Republic of Uzbekistan. When monotherapy was manifested by a decrease in the atherogenic index – an integral indicator that objectively reflects the total decrease in pro-atherogenic fractions: total cholesterol, triglycerides and LDL cholesterol and an increase in anti-atherogenic: HDL cholesterol. Moreover, the combined use of flaterone with atorvastatin 20 mg / day did not give ground in lipid-lowering efficacy, and its tolerance outranked to the effect of atorvastatin in a titrated dose of up to 40 mg / day (on average 32 mg). Conclusion. The results allow us to recommend the use of flateron in the form of monotherapy in patients with statin intolerance, and the combined treatment of flateron and atorvastatin in patients with intolerance to high doses of statins in order to achieve maximum hypolipidemic effect while there are no side effects.